| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() DG DISPATCH - WCO: Fosamax Effective For Men With Osteoporosis By W. A. Thomasson, PhD Special to DG News
CHICAGO, IL -- June 19, 2000 -- There is no drug approved currently for the treatment of osteoporosis in men. Rene Rizzoli, MD, of University Hospital in Geneva, Switzerland, told journalists covering the World Congress on Osteoporosis that this is about to change. Data presented Saturday (June 17) by Dr. Rizzoli and his colleagues show that Fosamax (alendronate sodium) reduces vertebral fracture in men as it does in women. The study, which was described as the first large, randomized, multi-center study ever conducted on male osteoporosis, enrolled 241 osteoporotic men aged 31 to 87 years. Half of these men already had vertebral fractures when the study began. Ninety-five subjects were randomized to receive placebo and 146 received Fosamax at a dose of 10 milligrams/day for two years. Over the course of the two-year follow-up, men receiving placebo experienced 5.3 non-vertebral fractures and 7.1 vertebral fractures. Fosamax-treated men experienced 4.1 non-vertebral fractures and 0.8 vertebral fractures. The difference in vertebral fractures is statistically significant (p = 0.017). The drug also eliminated the height loss that typically accompanies vertebral fracture. In addition, Fosamax-treated men also saw bone mineral density increases far greater than those seen in the control group (p < 0.001). Fosamax was also stated to be well tolerated, with similar rates of adverse events, including those in the upper gastrointestinal tract, between placebo and active-drug groups. "We have now a drug which is able to decrease the incidence of vertebral fracture in men with osteoporosis," Dr. Rizzoli concluded.
Related Link: Fosamax (alendronate sodium).
|